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ABSTRACT Fast, definitive diagnosis of Creutzfeldt-Jakob disease (CJD) is important in assessing patient care options and trans-
mission risks. Real-time quaking-induced conversion (RT-QuIC) assays of cerebrospinal fluid (CSF) and nasal-brushing speci-
mens are valuable in distinguishing CJD from non-CJD conditions but have required 2.5 to 5 days. Here, an improved RT-QuIC
assay is described which identified positive CSF samples within 4 to 14 h with better analytical sensitivity. Moreover, analysis of
11 CJD patients demonstrated that while 7 were RT-QuIC positive using the previous conditions, 10 were positive using the new
assay. In these and further analyses, a total of 46 of 48 CSF samples from sporadic CJD patients were positive, while all 39 non-
CJD patients were negative, giving 95.8% diagnostic sensitivity and 100% specificity. This second-generation RT-QuIC assay
markedly improved the speed and sensitivity of detecting prion seeds in CSF specimens from CJD patients. This should enhance
prospects for rapid and accurate ante mortem CJD diagnosis.
IMPORTANCE A long-standing problem in dealing with various neurodegenerative protein misfolding diseases is early and accu-
rate diagnosis. This issue is particularly important with human prion diseases, such as CJD, because prions are deadly, transmis-
sible, and unusually resistant to decontamination. The recently developed RT-QuIC test allows for highly sensitive and specific
detection of CJD in human cerebrospinal fluid and is being broadly implemented as a key diagnostic tool. However, as currently
applied, RT-QuIC takes 2.5 to 5 days andmisses 11 to 23% of CJD cases. Now, we have markedly improved RT-QuIC analysis of
human CSF such that CJD and non-CJD patients can be discriminated in a matter of hours rather than days with enhanced sen-
sitivity. These improvements should allow for much faster, more accurate, and practical testing for CJD. In broader terms, our
study provides a prototype for tests for misfolded protein aggregates that cause many important amyloid diseases, such as Alz-
heimer’s, Parkinson’s, and tauopathies.
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Among the numerous mammalian prion diseases or trans-missible spongiform encephalopathies (TSEs) is human
Creutzfeldt-Jakob disease (CJD), an incurable, fatal neurodegen-
erative disease. CJD can have genetic and acquired origins, but the
most common form is sporadic CJD (sCJD), which arises without
an identifiable genetic or infectious cause in about one person per
million per year worldwide. Although sCJD is not contagious, it is
transmissible to experimental animals and can be transmitted to
other humans by iatrogenic routes, such as corneal transplants,
neurosurgical procedures using contaminated instruments, or
growth hormone administration (for review, see reference 1).
Themolecular pathogenesis of TSEs involves the accumulation
of abnormal, infectivity-associated forms of prion protein (PrP)
which serve as disease-specificmarkers.While the normal form of
PrP, PrPSen, is mostly monomeric, protease sensitive, and rich in
-helices (2, 3), TSE-associated forms (e.g., PrPCJD) tend to be
multimeric (4–7), relatively protease resistant (8), and rich in
-sheet (2, 9–12). The extent of the protease-resistant core of
PrPCJD (e.g., type 1 or 2) and the patient’s alleles at PRNP codon
129 (encoding methionine [M] or valine [V]) define six different
sCJD subtypes, namely, MM1, MM2, MV1, MV2, VV1, and VV2
(for review, see reference 13).
The ability of TSE-associated forms of PrP, such as PrPCJD, to
seed the polymerization of recombinant PrPSen (rPrPSen) into am-
yloid fibrils that enhance the fluorescence of thioflavin T (ThT)
serves as the basis of sensitive assays for prion-associated seeding
activity (14–16). One of these assays, real-time quaking-induced
conversion (RT-QuIC), is often at least as sensitive as animal bio-
assays and useful for detecting prion-seeding activity in a wide
variety of tissues and fluids from TSE-infected hosts (15, 16).
Quantitation of relative levels of prion-seeding activity can be
achieved using endpoint dilution RT-QuIC (15) or, under more
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carefully controlled experimental conditions, comparisons of re-
action kinetics (17).
RT-QuIC testing of human cerebrospinal fluid (CSF) (18–20)
and olfactory mucosa (21) can be highly sensitive and specific in
discriminating sporadic and genetic CJD patients from non-CJD
controls. Because the current alternatives for definitive diagnosis
of CJD based on PrPCJD detection in living patients require brain
biopsies, RT-QuIC analysis of CSF is being broadly implemented
as a key diagnostic tool. However, one of the practical limitations
of current versions of the assay is that it typically takes 2.5 to 5 days
to analyzemost samples of diagnostic significance, such as human
CSF (18, 19) and olfactory mucosa (21). Furthermore, extensive
RT-QuIC analyses of CSF samples have shown that despite having
99 to 100%diagnostic specificity, the assay has failed to identify 11
to 23% of sporadic CJD cases (18, 19). Our recent exploratory
study of olfactory brushings by RT-QuIC increased diagnostic
sensitivity to 97% (21), but this sampling procedure awaits
larger-scale validation and implementation. In contrast, CSF sam-
ples are routinely collected from patients with suspected CJD as
part of screening for neurological disorders that mimic CJD but
are potentially treatable (22). Thus, CSF remains a primary diag-
nostic sample for testing by RT-QuIC. In this light, improvement
of the sensitivity of CSF testing by RT-QuIC is needed to provide
more accurate diagnostic information to guide decisions about
treating patients and reducing risks of iatrogenic CJD transmis-
sions. In the present study, we havemarkedly improved RT-QuIC
detection of prion-seeding activity in human CSF such that CJD
and non-CJD patients can be discriminated in a matter of hours
rather than days with enhanced sensitivity.
RESULTS
Enhanced detection of sCJD with CSF RT-QuIC by using trun-
cated substrate and SDS. For RT-QuIC-based sCJD diagnosis us-
ing CSF samples, full-length human or hamster rPrPSen substrates
(residues 23 to 231, i.e., Hu or Ha rPrPSen 23–231, respectively)
have been used successfully (18, 19). Here, we tested whether an
N-terminally truncated hamster rPrPSen (residues 90 to 231, i.e.,
Ha rPrPSen 90–231) might also improve sCJD detection in CSF
samples. Instead, we found initially that when pure CSF was ana-
lyzed, positive reactions occurred only with the full-length sub-
strate (compare Fig. 1A and B). However, pure CSF specimens
lack SDS that was present in the previously studied brain homog-
enates, so we also tested the effects of SDS on CSF-seeded reaction
mixtures using each of the substrates. Although with Ha rPrPSen
23–231, 0.002% SDS decreased the RT-QuIC responses to CSF
samples from two patients with definite sCJD (Fig. 1C), it mark-
edly enhanced the speed and strength of reactions containing Ha
rPrPSen 90–231 (Fig. 1D). Thus, combining Ha rPrPSen 90–231
with SDS gavemore rapid and robust RT-QuIC responses to sCJD
seeds in CSF than has been observed with previously described
conditions (18, 19).
FIG 1 Comparison of CSF RT-QuIC analyses using rHaPrPSen 23–231 or 90–231, with or without SDS. Two sCJD samples (red) and three nonneurological
control CSF samples (blue) were tested at 42°C by using full-length rHaPrPSen 23–231 (left) or truncated rHaPrPSen 90–231 (right) with (bottom) or without
(top) the addition of 0.002% SDS. Distinct symbols represent separate sCJD samples. In the reaction mixtures containing rHaPrPSen 90–231 and SDS (bottom
right), one of the three nonneurological control samples showed prion-independent fibril formation near 80 h, but this is more than 50 h after the established
cutoff time point for these conditions (see Materials and Methods). Symbols show the mean fluorescence from four technical replicate wells.
Orrú et al.















Further acceleration of sCJD CSF RT-QuIC with increased
temperature. To further improve upon the new conditions de-
scribed above (containing SDS and rHaPrPSen 90–231), we in-
creased the RT-QuIC reaction temperature from 42°C to 55°C.
The higher incubation temperature reduced the lag phase of reac-
tions seeded with sCJD CSF by at least 4-fold, without eliciting
false-positive responses in the reactions seededwith non-CJDCSF
(Fig. 2).
New conditions for CSF RT-QuIC improve speed and sensi-
tivity of sCJD detection. We then applied RT-QuIC using the
combination of the rHaPrPSen 90–231 substrate, 55°C, and
0.002% SDS (referred to here as improved QuIC-CSF [IQ-CSF]
conditions) to an initial panel of 11 CSF samples from probable
and definite sCJD patients. This panel included the following
sCJD subtypes: MM1 (n 3), MV1 (n 1), VV2 (n 1), MM (n
 2), MV (n 1), and VV (n 1) of unknown PrPCJD type and
two of unknown PRNP genotype (Fig. 3). We also tested the same
samples in parallel using the RT-QuIC conditions that were estab-
lished previously for sCJD diagnosis using CSF samples, i.e., Ha
rPrPSen 23–231, 42°C, and no SDS (referred to here as previous
QuIC-CSF [PQ-CSF] conditions) (19). Ten of 11 sCJD samples
tested with the IQ-CSF conditions gave strong positive reactions
in less than 10 h (Fig. 3, red circles). In contrast, with the PQ-CSF
conditions, only 7 of 11 of the samples gave positive reactions
within 90 h, with much slower reaction kinetics and weaker over-
all fluorescence enhancements (Fig. 3, blue triangles). Notably, of
the 4 samples that did not give positive responses under the PQ-
CSF conditions, 3 gave strong and rapid responses using the IQ-
CSF conditions (Fig. 3C, D, F, and G), while samples from non-
CJD control cases remained negative (Fig. 3L). These findings
provided initial evidence that our new reaction conditions im-
prove the speed and diagnostic sensitivity of RT-QuIC using CSF
samples.
CSF endpoint dilution analysis using new RT-QuIC condi-
tions. To directly compare the analytical sensitivities of RT-QuIC
using the PQ-CSF and IQ-CSF conditions, we tested serial dilu-
tions of 4 sCJD CSF samples that gave positive reactions under
both conditions in the above-described analyses (Fig. 4). Four
replicate reactions were tested per sample. Using Spearman-
Karber analysis of the data (23), we estimated the volume of pure
CSF required to give 50% positive replicate wells under each con-
dition (the 50% seeding dose [SD50]). For 3 of the patients’ spec-
imens, the required volume was 5- to 36-fold lower using the new
IQ-CSF conditions while being nearly equivalent for the 4th spec-
imen. Thus, these endpoint dilution measurements confirmed
that, in the majority of cases, the IQ-CSF conditions provided not
only faster but also more analytically sensitive RT-QuIC reactions
than did PQ-CSF conditions.
Analysis of an additional blinded panel of CJD and non-CJD
CSF samples. For further evaluation of the performance of the
IQ-CSF conditions, we tested another 76 CSF samples from prob-
able or definite sCJD patients as well as both neurological disease
and healthy controls to give a total sample size of 87. Table 1
summarizes characteristics of all of the cases and controls tested
with the IQ-CSF conditions so far. Figure 5 shows the RT-QuIC
results from the sCJD (red) and non-CJD (orange) samples. Con-
sistent with the results in Fig. 3, we saw rapid and strong responses
from 46 of 48 sCJD CSF samples using the IQ-CSF conditions
(Fig. 5A and B), while 1 definite sCJD (MM1) CSF sample, 1
probable sCJD (type unknown) CSF sample, and all 39 negative
non-CJD controls gave no ThT fluorescence enhancement within
55 h, according to positivity criteria described in Materials and
Methods. The peak relative fluorescence values from the individ-
ual sCJD and non-CJD samples are shown in Fig. 5B, and the lag
times to the threshold for positive responses are shown in Fig. 5C.
For many of these samples, we lacked enough volume to also test
them with the PQ-CSF conditions, but these conditions have al-
ready been tested extensively (19, 21). Thus, for comparison of the
PQ-CSF conditions to our present IQ-CSF assay results, we show
data derived from our previously published analyses of an over-
lapping panel of CSF samples (21), which indicated much slower
and weaker RT-QuIC responses than those obtained with the new
conditions (Fig. 5A and C). Furthermore, with the latter condi-
tions, 85% of the sCJD CSF samples gave positive reactions in all
of their individual replicate reactions, whereas this was true of
only 38%of the sCJD samples tested using the PQ-CSF conditions
(data not shown). Overall, the positive RT-QuIC tests from 46/48
sCJD cases using the IQ-CSF conditions indicated a sensitivity of
96% (95% confidence interval [CI] 85 to 99%). By comparison,
the sensitivity that we have obtained using the PQ-CSF conditions
was 77% (CI 57 to 89%) (21), which was significantly lower (P
 0.02 by two-sided Fisher exact test) than our sensitivity with the
IQ-CSF conditions. The negative responses from all of the non-
CJD samples indicated a nominal specificity of 100% (CI 89 to
100%), which is consistent with data from previously described
RT-QuIC conditions (18, 19, 21). Taken together, these results
indicated that the new IQ-CSF conditions improved the speed and
sensitivity of the RT-QuIC CSF assay for sCJD while maintaining
full specificity.
DISCUSSION
Improved ante mortem diagnostic testing for CJD would have sig-
nificant value in medical and public health practice for several
reasons. Although quick and accurate diagnoses are helpful in
dealing with any disease, rapid detection of CJD infections is par-
ticularly important in order to prevent iatrogenic transmissions. A
recurring scenario is one that occurred recently in two different
United States hospitals: medical instruments were used on CJD-
infected patients and then on many other individuals before CJD
was suspected in the original patients. Because routine disinfec-
FIG 2 Increased temperature accelerated RT-QuIC detection of sCJD in CSF.
Comparison of individual CSF samples (circles or triangles) at either 42°C
(gold) or 55°C (red) using the rHaPrPSen 90–231 substrate in the presence of
0.002% SDS. Negative controls are displayed for both 42°C (blue lines) and
55°C (green line). The symbols represent the means from four technical rep-
licate reactions.
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tion procedures are not adequate for CJD decontamination, such
incidents can create risks of secondary hospital exposures (24).
CJD remains untreatable, but accurate testing that can either rule
in or rule out the disease should help to guide decisions about
treatment options. With a progressive disease like CJD, the earlier
the diagnosis can be established, the more likely it is that effective
treatments can be developed. Finally, epidemiological surveillance
of CJD, which currently relies heavily on autopsy-based diagnosis,
could bemore efficient, cost-effective, and broadly applicablewith
RT-QuIC testing of samples that can be obtained without autop-
sies.
Multiple CJD diagnostic laboratories around the world are im-
plementing and validating RT-QuIC testing for human sCJD CSF
using conditions similar to our PQ-CSF conditions (e.g., see ref-
erences 19 and 21).Othermajor centers have also extensively eval-
uated other RT-QuIC conditions for CJD testing, including full-
length human rPrPSen (residues 23 to 231) as the substrate, 37°C,
andno SDS (18, 20) or a chimeric hamster-sheep rPrPSen (residues
14 to 231), 42°C, and no SDS (25). For each of these previously
described conditions, the vast majority of the RT-QuIC-positive
reaction mixtures seeded with human sCJD CSF samples become
positive between 24 and 90 h. Our new conditions reduce that
time to 4 to 14 h while increasing sensitivity relative to our own
testing using the PQ-CSF conditions.Other previous studies using
PQ-CSF-like conditions but with different instruments, shaking
motions, and speeds have obtained somewhat higher diagnostic
sensitivities (89% [CI  83 to 95%]) (19). Determining whether
the latter sensitivity is significantly lower than our current 96%
(CI  85 to 99%) sensitivity with the IQ-CSF conditions will
require comparisons of much larger sample sets. However, it is
clear that compared on identical instruments, the IQ-CSF condi-
tionsmarkedly improved not only the speed but also the analytical
and diagnostic sensitivities of RT-QuIC analysis of CSF samples.
The mechanistic reasons for the improvements with the IQ-
FIG 3 Comparison of PQ-CSF and IQ-CSF RT-QuIC analyses of individual sCJD and negative-control CSF samples. CSFs were tested with either the IQ-CSF
(red circles) or PQ-CSF (blue triangles) conditions. The latter data have been reported previously (21). Traces from 2 non-neurological control (NNC) samples
analyzed with the IQ-CSF conditions are reported in panel l (green circles). Due to technical issues, traces in panels i and k end at 45 h. Nevertheless, using both
conditions, these samples were called positive based on the criteria established inMaterials andMethods. Symbols indicate themeans from three or four replicate
wells. Color-matched fractions indicate the number of positive wells out of the total number of replicate reactions for each sample.
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CSF conditions are not clear and are likely to be complex. With
respect to the hamster rPrPSen substrate, our data indicated that
removal of unstructured N-terminal residues 23 to 89 allowed for
much faster sCJD CSF-seeded reactions, but only when the reac-
tionmixture is supplementedwith SDS (Fig. 1). Paradoxically, the
addition of SDS to reaction mixtures with the full-length hamster
rPrPSen substrate inhibited the reactions. Thus, there appears to be
a synergistic beneficial effect of adding SDS and removing rPrPSen
23–89. Because the effect of SDS is dependent on the type of
rPrPSen, it is likely that the detergent is affecting the substrate
rather than the sCJD seeds in CSF. We note that increasing SDS
above 0.002% was detrimental to the speed and intensity of sCJD
CSF-seeded RT-QuIC responses (data not shown). Beyond that,
we can only speculate that the combined effects of SDS and sub-
FIG 4 Endpoint dilution analyses of 4 sCJD CSF samples using PQ-CSF and IQ-CSF conditions. Reaction mixtures seeded with serial dilutions of sCJD CSF
samples (20- to 0.08-l equivalents of pure CSF as designated) were tested with the PQ-CSF (shades of blue) and IQ-CSF (shades of red) conditions. Each panel
shows results from an individual sCJD patient specimen. Spearman-Karber estimates of the volume of pure CSF equivalents giving 50% positive replicate wells
(SD50) under the IQ-CSF (red) or PQ-CSF (blue) conditions are also indicated. The fold difference in the SD50 values (black, ) indicates the relative analytical
sensitivities obtained under the PQ-CSF and IQ-CSF conditions for the given sCJD CSF specimen. Individual traces represent means from four replicate
reactions.
TABLE 1 CSF RT-QuIC, 14-3-3, and Tau results with clinical and demographic profiles of sCJD and negative-control patients
Patient type
No. of positive samples/total no. of samples
Age in yrs SD GenderIQ-CSF RT-QuIC assay 14-3-3 assay Tau assay (2,400 pg/ml)
sCJD patientsa 46/48 47/48 40/47 68 11 Male, 22; female, 26
MM1 17/18 18/18 16/17
MV1 7/7 7/7 5/7
MV2 5/5 4/5 1/5
VV2 7/7 7/7 7/7
ND1 6/6 6/6 6/6
MM 2/2 2/2 2/2
MV 1/1 1/1 1/1
VV 1/1 1/1 1/1
ND 0/1 1/1 1/1
Control patientsb 0/39 3/34 0/36 69 11 Male, 17; female, 22
Neurological 0/30 3/28 0/30
Nonneurological 0/9 0/6 0/6
a When available, the patients’ protein gene (PRNP) codon 129, heterozygous or homozygous for methionine (M) or valine (V), and the classification of the protease-resistant core
of PrPCJD (type 1 or 2) are reported. Patients who were not genotyped were classified as not done (ND).
b Control patients were classified as either “non-neurological,” displaying no neurological symptoms at the time of CSF collection, or “neurological.” Neurological patients had a
mixture of diagnoses, as listed in Materials and Methods.
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strate truncation might alter one or more of the following: sub-
strate stability, the formation of on- or off-pathway states or in-
termediates, the interactions between seed and substrate, and/or
the stability or seeding capacity of the nascent rPrP amyloid prod-
uct. With respect to temperature, we expect that higher tempera-
tures could destabilize the substrate to make it more rapidly con-
vertible to amyloid, increase the intermolecular collisions between
seed and substrate, or promote secondary nucleation by promot-
ing shearing of nascent rPrP amyloid fibrils to generatemore seed-
ing sites. Much additional study will be required to distinguish
among these many possibilities.
MATERIALS AND METHODS
Cerebrospinal fluid samples. Cerebrospinal fluid samples (0.5 ml)
were obtained from patients with possible or probable Creutzfeldt-Jakob
disease at the time of sampling, as well as from the patients with other
neurologic disorders, including Alzheimer’s disease (6 patients), amyo-
trophic lateral sclerosis (4 patients), atypical Parkinsonism (1 patient),
dementia (2 patients), dystonia (1 patient), encephalitis (1 patient), fron-
totemporal dementia (3 patients), Lewy body dementia (1 patient), mild
cognitive impairment (7 patients), myclonus (1 patient), or rapidly pro-
gressive dementia (3 patients) (Table 1). Nonneurological cerebrospinal
fluid control samples were purchased from Innovative Research or ob-
tained from the Neuropathology Laboratory at Verona University Hospi-
tal. All cerebrospinal fluid samples were stored at 80°C from a time
shortly after harvest until use in this assay.
The study was approved by the ethics committee at Istituto Superiore
di Sanità (Italy), which is recognized by the Office for Human Research
Protections of the U.S. Department of Health and Human Services. In-
formed consent for participation in research was obtained in accordance
with the Declaration of Helsinki and the Additional Protocol to the Con-
vention on Human Rights and Biomedicine, concerning Biomedical Re-
search. All the sampling of CSFwas performed after informed consentwas
obtained from each patient or the patient’s representative. The analyses of
human specimens that were performed at the NIAID were performed
under exemption number 11517 for the use of encoded samples from the
NIH Office of Human Subjects Research Protections.
Recombinant prion protein purification.Recombinant PrP was pre-
pared as previously described (15). Briefly, Escherichia coli carrying the
vector with the PrP sequence (Syrian hamster residues 23 to 231 [Gen-
Bank accession number K02234] or residues 90 to 231) was grown in
Luria broth (LB) medium in the presence of kanamycin and chloram-
phenicol. Protein expression was induced using Overnight Express auto-
induction system 1 (Novagen). Recombinant PrP was purified from in-
clusion bodies under denaturing conditions using Ni-nitrilotriacetic acid
(NTA) superflow resin (Qiagen) with an ÄKTA fast protein liquid chro-
matographer (FPLC). The protein was refolded on the column using a
guanidine HCl reduction gradient and eluted using an imidazole gradient
as described (15). The purified protein was extensively dialyzed into 10
mM sodium phosphate buffer (pH 5.8). Protein concentration was deter-
mined by absorbance measured at 280 nm. Following filtration (0.22-m
syringe filter [Fisher]), recombinant PrP was aliquoted and stored at
80°C. Prior to use, the protein was filtered again (100-kDa spin filter
[Pall]), and the concentration was again determined.
RT-QuIC. Real-time QuIC (RT-QuIC) assays were performed as re-
ported previously for CSF (21) except where indicated. Briefly, the basic
RT-QuIC reaction mix contained 10 mM phosphate buffer (pH 7.4),
300 mM NaCl, 0.1 mg/ml rPrPSen, 10 M thioflavin T (ThT), and 1 mM
ethylenediaminetetraacetic acid tetrasodium salt (EDTA). Reactions were
runwith eitherHa rPrPSen 23–231 or 90–231with orwithout the addition
of 0.002% SDS to the reactionmix. Eighty microliters of reactionmix was
loaded into a black 96-well plate with a clear bottom (Nunc), and reaction
mixtures were seeded with 20 l of CSF for a final reaction volume of
100 l. Plates were sealed (Nalgene Nunc International sealer) and incu-
bated in a BMG FLUOstar Omega plate reader at either 42 or 55°C for 55
FIG 5 Averaged kinetics, peak fluorescence, and times to threshold using PQ-CSF
and/or IQ-CSF conditions. (A) Averaged RT-QuIC kinetics for sCJD and non-CJD
CSF samples. Mean ThT fluorescence for all tested CSF specimens from non-CJD
control(greenandorange)andsCJD(blueandred)patientsunderPQ-CSF(triangles)
or IQ-CSF (circles) conditions are shown.Traces denote themeans (standarddevi-
ation[SD])frombiologicalreplicatesforeachcategoryasindicatedbythelegend.Each
biological replicatewas in turn an average from three or four technical replicatewells.
PQ-CSF data were previously reported (21). (B) Peak fluorescence values for CSF
samplesanalyzedwiththeIQ-CSFprotocol.Theaveragepeakfluorescencevaluefrom
all 48 sCJD samples (red squares) and 39 control samples (orange circles) tested
blinded using the IQ-CSF conditions is shown for each individual sample withmean
(horizontal line) and standarddeviations (vertical lines).Thedashed line indicates the
positivity threshold (seeMaterials andMethods). (C) Times to threshold (defined in
Materials and Methods) for individual sCJD RT-QuIC-positive CSF samples tested
with thePQ-CSF (blue circles; derived frompreviously reported experiments [21]) or
IQ-CSF (red squares) conditions (this study) are shown. Themean (horizontal line)
and standard deviations (vertical lines) are displayed for each testing condition.
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to 90 h with cycles of 60 s of shaking (700 rpm, double-orbital) and 60 s of
rest throughout the incubation. ThT fluorescence measurements (excita-
tion, 450  10 nm; emission, 480  10 nm [bottom read]) were taken
every 45 min.
Data analysis. To compensate for minor differences between fluores-
cence plate readers, including baseline differences, we normalized the val-
ues to a percentage of the maximal fluorescence response of the plate
readers as described (21). These normalized values were plotted versus
reaction time.
Samples were judged to be RT-QuIC positive by using criteria similar
to those previously described for RT-QuIC analyses of CSF specimens (19,
21), using baseline-adjusted, normalized fluorescence values and suitably
adjusted cutoff values (21). Our discrimination criteria are briefly de-
scribed as follows. The threshold was calculated as the mean value at the
time of assessment from all negative-control samples plus 10 standard
deviations. However, given the signal strength and rapid response, a
stricter threshold of 10% was set beyond the calculated threshold to de-
crease the likelihood of false positives. A sample was considered positive if
themean of the highest two normalized fluorescence values from replicate
wells was higher than a predetermined threshold and at least two out of
four replicatewells crossed that threshold (21). If only three replicatewells
were run, then only the average value of all three wells was considered. For
PQ-CSF conditions, positive/negative assessments were made at the 90-h
time point. For IQ-CSF conditions, positive/negative results were scored
based on the highest peak value prior to 24 h to account for the signal
degradation over time. For sensitivity determinations, IQ-CSF conditions
were assessed out to 55 h.
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